These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14500583)

  • 1. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
    Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
    Clin Chem; 2003 Oct; 49(10):1579-98. PubMed ID: 14500583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
    Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
    Clin Breast Cancer; 2004 Jun; 5(2):105-16. PubMed ID: 15245613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
    Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
    Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.
    Barić M; Kulić A; Sirotković-Skerlev M; Dedić Plavetić N; Vidović M; Horvatić-Herceg G; Vrbanec D
    Pathol Oncol Res; 2015 Jul; 21(3):589-95. PubMed ID: 25367073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
    Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
    Köstler WJ; Schwab B; Singer CF; Neumann R; Rücklinger E; Brodowicz T; Tomek S; Niedermayr M; Hejna M; Steger GG; Krainer M; Wiltschke C; Zielinski CC
    Clin Cancer Res; 2004 Mar; 10(5):1618-24. PubMed ID: 15014012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
    Shao X; Wang X; Xu X; Feng J; Han M; Zhang H; Chen ZH; Wang S; Zang YM; Huang P; Jin H; Wang X
    Int J Clin Exp Pathol; 2014; 7(3):1108-13. PubMed ID: 24696727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of HER-2/neu oncoprotein in breast cancer.
    Molina R; Escudero JM; Muñoz M; Augé JM; Filella X
    Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].
    Mathelin C; Croce S; Rault S; Gharbi M; Eichler F; Gairard B; Coumaros G; Koehl C
    Presse Med; 2011 Feb; 40(2):126-37. PubMed ID: 21074348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum HER-2/neu in the management of breast cancer patients.
    Lüftner D; Lüke C; Possinger K
    Clin Biochem; 2003 Jun; 36(4):233-40. PubMed ID: 12810150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.
    Köstler WJ; Steger GG; Soleiman A; Schwab B; Singer CF; Tomek S; Brodowicz T; Krainer M; Wiltschke C; Horvat R; Jakesz R; Zielinski CC
    Anticancer Res; 2004; 24(2C):1127-30. PubMed ID: 15154635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
    Zheng H; Zhong A; Xie S; Wang Y; Sun J; Zhang J; Tong Y; Chen M; Zhang G; Ma Q; Kai J; Guo L; Lu R
    Cancer Med; 2019 Feb; 8(2):679-685. PubMed ID: 30661303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
    Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
    Witzel I; Thomssen C; Krenkel S; Wilczak W; Bubenheim M; Pantel K; Neumann R; Jänicke F; Müller V
    Int J Biol Markers; 2006; 21(3):131-40. PubMed ID: 17013794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
    Tsai HP; Chen SC; Chien HT; Jan YY; Chao TC; Chen MF; Hsieh LL
    World J Surg Oncol; 2012 Feb; 10():42. PubMed ID: 22339939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
    J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.